Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial

Fig. 2

Proportion of Patients with a Baseline Imputed PaO2/FiO2 ≤ 200 in Each Ordinal Scale Category Over Time. A higher proportion of patients receiving Auxora were discharged, and a lower proportion progressed to invasive mechanical ventilation, ECMO, and death at Day 60 (Odds Ratio, 0.647; 95% CI 0.405, 1.031; P = 0.0672) and Day 30 (Odds Ratio, 0.617; 95% CI 0.387, 0.983; P = 0.0423). Efficacy outcome measured with the 8-point ordinal scale included recovery rate defined as the first day the patient satisfied criteria 6, 7, or 8 and change in the 8-point ordinal scale over time. The proportions are compared between the two treatment groups using a proportional odds model with a fixed factor of treatment groups. ECMO, Extracorporeal membrane oxygenation

Back to article page